Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug puzzle: study aims to untangle polypharmacy risks

NCT ID NCT07640854

Knowledge-focused Sponsor: National Medical Research Center for Therapy and Preventive Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 130 people with chronic heart failure to understand how taking multiple medications (polypharmacy) affects their safety, adherence, and health outcomes. Researchers will look for patterns of over- or under-prescribing and factors linked to low medication adherence. The goal is to improve prescribing practices and reduce emergency hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand how to prescribe medications safely for heart failure patients taking many drugs, potentially reducing hospital visits and improving quality of life.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a new therapy. The findings may not apply to all heart failure patients, and results depend on accurate reporting from participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study included patients with a confirmed diagnosis of chronic heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF), verified by echocardiography within 3 months before enrollment. All participants provided written informed consent. Patients with documented mental disorders or severe cognitive impairment were excluded

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with a confirmed diagnosis of chronic heart failure with reduced or mildly reduced ejection fraction (HFrEF / HFmrEF). 2. Diagnosis of HFrEF or HFmrEF confirmed by echocardiography within 3 months prior to enrollment. 3. Signed informed consent. Exclusion Criteria: 1. Documented mental disorders. 2. Severe cognitive impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure with reduced and mildly reduced ejection fraction (hfref and hfmref) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systolic heart failure Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic heart failure with reduced and mildly reduced ejection fraction (hfref and hfmref)

Contacts and locations

Locations

  • National Medical Research Centre for Therapy and Preventive Medicine

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.